Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drugstore.com

This article was originally published in The Tan Sheet

Executive Summary

Online retailer's net sales increase 41% to $84.3 mil. with a net loss of $6.3 mil. in the firm's third quarter, drugstore.com reports Oct. 26. Over-the-counter segment revenues rose 37% to $35.2 mil. due in part to a wider array of nutritional products. CEO Dawn Lepore says the firm has made "encouraging progress in a number of key areas despite a critical management transition and a seasonally challenging period." Lepore took over as CEO in September (1"The Tan Sheet" Sept. 27, 2004, In Brief)...

You may also be interested in...



Drugstore.com leadership

Online retailer appoints Dawn Lepore as CEO, effective Oct. 11. Lepore currently is VP-technology, operations and administration at Charles Schwab, a member of Schwab's executive committee and a trustee of SchwabFunds; she will relinquish all of her Schwab positions when she joins Drugstore.com. Drugstore.com board member Melinda Gates says Lepore "brings a great deal of respect and depth from the e-commerce industry as both a leader and an innovator," having designed Schwab's "entire technology platform" and played a "key role" in that firm's online brokerage business. Lepore replaces interim CEO and current CFO Robert Barton, who took over after Kal Raman stepped down in June (1"The Tan Sheet" June 14, 2004, In Brief)...

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Topics

UsernamePublicRestriction

Register

PS097452

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel